Mechanisms for cachexia in heart failure

Current Heart Failure Reports

Volumn 10, Issue 4, 2013, Pages 307-314

  Pureza, Vincent ^a   Florea, Viorel G ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anabolic catabolic imbalance; Cachexia; Cytokines; Heart failure; Immunological activation; Neurohormonal activation; Obesity paradox; Tumor necrosis factor alpha

Indexed keywords

ANABOLIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; FISH OIL; GLUTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MEGESTROL ACETATE; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NEUROHORMONE; OXIDIZING AGENT; OXYMETHOLONE; PENTOXIFYLLINE; ROSUVASTATIN; TRACE ELEMENT; VITAMIN;

ARTICLE; BIOSYNTHESIS; CACHEXIA; CATABOLISM; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; GASTROINTESTINAL DISEASE; HEART FAILURE; HUMAN; HYPERTENSION; MUSCLE ATROPHY; NUTRITIONAL DISORDER; OBESITY; WEIGHT REDUCTION;

CACHEXIA; CYTOKINES; HEART FAILURE; HUMANS; NEUROTRANSMITTER AGENTS; OBESITY;

EID: 84888023297     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0153-9     Document Type: Article

References (97)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-90.
2. von Haehling S, Doehner W, Anker SD. Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure. Cardiovasc Res. 2007;73:298-309.
3. Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation. 1997;96:526-34.
4. Katz AM, Katz PB. Diseases of the heart in the works of Hippocrates. Br Heart J. 1962;24:257-64.
5. Wolfram S, Anker SD. Cardiac cachexia: pathophysiology and clinical implications. Basic Appl Myol. 2003;13:191-201.
6. Anker SD, Negassa A, Coats AJ, et al. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet. 2003;361:1077-83.
7. Cowie MR, Mosterd A, Wood DA, et al. The epidemiology of heart failure. Eur Heart J. 1997;18:208-25.
8. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72:S3-9.
9. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050-3.
10. Anker SD, Laviano A, Filippatos G, et al. ESPEN Guidelines on Parenteral Nutrition: on cardiology and pneumology. Clin Nutr. 2009;28:455-60.
11. Velloso LG, Csengeri LF, Alonso RR, et al. Malnutrition in dilated cardiomyopathy. Correlation with echocardiographic indices of left ventricular function. Arq Bras Cardiol. 1992;58:189-92.
12. Gibbs CR, Jackson G, Lip GY. ABC of heart failure. Non-drug management. BMJ. 2000;320:366-9.
13. Vescovo G, Serafini F, Facchin L, et al. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart. 1996;76:337-43.
14. May PE, Barber A, D'Olimpio JT, et al. Reversal of cancer-related wasting using oral supplementation with a combination of beta-hydroxy-beta- methylbutyrate, arginine, and glutamine. Am J Surg. 2002;183:471-9.
15. Stein TP, Donaldson MR, Leskiw MJ, et al. Branched-chain amino acid supplementation during bed rest: effect on recovery. J Appl Physiol. 2003;94:1345-52.
16. Vasan RS, Beiser A, D'Agostino RB, et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA. 2003;289:1251-7.
17. Sundstrom J, Sullivan L, D'Agostino RB, et al. Plasma homocysteine, hypertension incidence, and blood pressure tracking: the Framingham Heart Study. Hypertension. 2003;42:1100-5.
18. Xin W, Wei W, Li X. Effects of fish oil supplementation on inflammatory markers in chronic heart failure: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2012;12:77.
19. Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561-9.
20. Arutyunov GP, Kostyukevich OI, Serov RA, et al. Collagen accumulation and dysfunctional mucosal barrier of the small intestine in patients with chronic heart failure. Int J Cardiol. 2008;125:240-5.
21. Raja K, Kochhar R, Sethy PK, et al. An endoscopic study of upper-GI mucosal changes in patients with congestive heart failure. Gastrointest Endosc. 2004;60:887-93.
22. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41.
23. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-6.
24. Deswal A, Petersen NJ, Feldman AM. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation. 2001;103:2055-9.
25. Tracey KJ, Morgello S, Koplin B, et al. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia. J Clin Invest. 1990;86:2014-24.
26. Bolger AP, Anker SD. Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications. Drugs. 2000;60:1245-57.
27. Yndestad A, Damas JK, Oie E, et al. Systemic inflammation in heart failure - the whys and wherefores. Heart Fail Rev. 2006;11:83-92.
28. Seta Y, Shan K, Bozkurt B, et al. Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail. 1996;2:243-9.
29. Hasper D, Hummel M, Kleber FX, et al. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761-5.
30. von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85:173-83.
31. Anker SD, Egerer KR, Volk HD, et al. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure. Am J Cardiol. 1997;79:1426-30.
32. Niebauer J, Volk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet. 1999;353:1838-42.
33. Rauchhaus M, Koloczek V, Volk H, et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol. 2000;76:125-33.
34. Anker SD, Ponikowski PP, Clark AL, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur Heart J. 1999;20:683-93.
35. Anand IS, Florea VG. Traditional and novel approaches to management of heart failure: successes and failures. Cardiol Clin. 2008;26:59-72.
36. Mann DL, Kent RL, Parsons B, Cooper IV G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation. 1992;85:790-804.
37. Obisesan TO, Toth MJ, Donaldson K, et al. Energy expenditure and symptom severity in men with heart failure. Am J Cardiol. 1996;77:1250-2.
38. Anand IS, Fisher LD, Chiang YT, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation. 2003;107:1278-83.
39. Brasier AR, Recinos 3rd A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22:1257-66.
40. Werner C, Werdan K, Ponicke K, Brodde OE. Impaired beta-adrenergic control of immune function in patients with chronic heart failure: reversal by beta1-blocker treatment. Basic Res Cardiol. 2001;96:290-8.
41. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J. 2005;26:2368-74.
42. Boxall BW, Clark AL. Beta-blockers and weight change in patients with chronic heart failure. J Card Fail. 2012;18:233-7.
43. Coats AJ, Anker SD, Roeker EB, et al. Prevention and reversal of cardiac cachexia in patients with severe heart failure by carvedilol: results of the COPERNICUS study. Circulation. 2001;104:437.
44. Pittman JG, Cohen P. The pathogenesis of cardiac cachexia. N Engl J Med. 1964;271:403-9.
45. Toth MJ, LeWinter MM, Ades PA, Matthews DE. Impaired muscle protein anabolic response to insulin and amino acids in heart failure patients: relationship with markers of immune activation. Clin Sci (Lond). 2010;119:467-76.
46. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009;121:227-52.
47. Underwood L, Van Wyk J. Normal and aberrant growth. In: Wilson J, Foster D, editors. Williams textbook of endocrinology. Philadelphia: WB Saunders; 1992. p. 1079-138.
48. Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Card Fail. 2003;9:219-26.
49. Isgaard J, Bergh CH, Caidahl K, et al. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J. 1998;19:1704-11.
50. Osterziel KJ, Strohm O, Schuler J, et al. Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet. 1998;351:1233-7.
51. Frustaci A, Gentiloni N, Russo MA. Growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med. 1996;335:672-4.
52. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407:908-13.
53. Nagaya N, Uematsu M, Kojima M, et al. Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic/catabolic factors. Circulation. 2001;104:2034-8.
54. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation. 2004;110:3674-9.
55. Tatemoto K, Carlquist M, Mutt V. Neuropeptide Y - a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982;296:659-60.
56. Krysiak R, Obuchowicz E, Herman ZS. Interactions between the neuropeptide Y system and the hypothalamic-pituitary-adrenal axis. Eur J Endocrinol. 1999;140:130-6.
57. Feng Q, Lambert ML, Callow ID, Arnold JM. Venous neuropeptide Y receptor responsiveness in patients with chronic heart failure. Clin Pharmacol Ther. 2000;67:292-8.
58. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372:425-32.
59. Houseknecht KL, Baile CA, Matteri RL, et al. The biology of leptin: a review. J Anim Sci. 1998;76:1405-20.
60. Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha. Int J Cardiol. 2002;83:73-81.
61. •• Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1:93-102. This review discusses the obesity paradox and its implication in heart failure.
62. Horwich TB, Fonarow GC, Hamilton MA, et al. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001;38:789-95.
63. Fonarow GC, Srikanthan P, Costanzo MR, et al. An obesity paradox in acute heart failure: analysis of body mass index and inhospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J. 2007;153:74-81.
64. Mohamed-Ali V, Goodrick S, Bulmer K, et al. Production of soluble tumor necrosis factor receptors by human subcutaneous adipose tissue in vivo. Am J Physiol. 1999;277:E971-5.
65. Lavie CJ, Cahalin LP, Chase P, et al. Impact of cardiorespiratory fitness on the obesity paradox in patients with heart failure. Mayo Clin Proc. 2013;88:251-8.
66. McAuley PA, Artero EG, Sui X, et al. The obesity paradox, cardiorespiratory fitness, and coronary heart disease. Mayo Clin Proc. 2012;87:443-51.
67. • Okoshi MP, Romeiro FG, Paiva SA, Okoshi K. Heart failure-induced cachexia. Arq Bras Cardiol. 2013;100:476-82. This review discusses the pathophysiology of cardiac cachexia.
68. Mustafa I, Leverve X. Metabolic and nutritional disorders in cardiac cachexia. Nutrition. 2001;17:756-60.
69. Downing J, Balady GJ. The role of exercise training in heart failure. J Am Coll Cardiol. 2011;58:561-9.
70. Kinugawa T, Kato M, Ogino K, et al. Interleukin-6 and tumor necrosis factor-alpha levels increase in response to maximal exercise in patients with chronic heart failure. Int J Cardiol. 2003;87:83-90.
71. Sigurdsson A, Swedberg K, Ullman B. Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure. Eur Heart J. 1994;15:247-54.
72. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High- versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol. 1998;32:1811-8.
73. Liu L, Zhao SP. The changes in circulating tumor necrosis factor levels in patients with congestive heart failure influenced by therapy. Int J Cardiol. 1999;69:77-82.
74. Corbalan R, Acevedo M, Godoy I, et al. Enalapril restores depressed circulating insulin-like growth factor 1 in patients with chronic heart failure. J Card Fail. 1998;4:115-9.
75. Tsutamoto T, Wada A, Maeda K, et al. Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. J Am Coll Cardiol. 2000;35:714-21.
76. Anker SD, Lechat P, Dargie HJ. Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS-II study. J Am Coll Cardiol. 2003;41:156A-7.
77. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. Pharmacol Res. 2006;53:482-91.
78. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med. 1989;320:265-71.
79. Sharma R, Anker SD. Cytokines, apoptosis and cachexia: the potential for TNF antagonism. Int J Cardiol. 2002;85:161-71.
80. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224-6.
81. Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail. 2002;4:559-61.
82. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-40.
83. Anker SD, Coats AJ. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int J Cardiol. 2002;86:123-30.
84. Doherty GM, Jensen JC, Alexander HR, et al. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery. 1991;110:192-8.
85. Zabel P, Wolter DT, Schonharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet. 1989;2:1474-7.
86. Skudicky D, Bergemann A, Sliwa K, et al. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation. 2001;103:1083-8.
87. Sliwa K, Skudicky D, Candy G, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail. 2002;4:305-9.
88. Shaw SM, Shah MK, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail. 2009;11:113-8.
89. Caminiti G, Volterrani M, Iellamo F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919-27.
90. Tomoda H. Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. Am J Cardiol. 1999;83:123-5.
91. Vadell C, Segui MA, Gimenez-Arnau JM, et al. Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia. Am J Clin Oncol. 1998;21:347-51.
92. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail. 2002;8:216-24.
93. Krum H, Ashton E, Reid C, et al. Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail. 2007;13:1-7.
94. Sola S, Mir MQ, Lerakis S, et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332-7.
95. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100:2671-9.
96. Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877-83.
97. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248-61.